New treatment options for nonmetastatic osteosarcoma: focus on mifamurtide in adolescents

References

• Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531–1543.
   PubMed Web of Science ®Google Scholar
• Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 2011;47(16):2431–2445.
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–790.
   PubMed Web of Science ®Google Scholar
• Daw NC, Neel MD, Rao BN, et al. Frontline treatment of localized osteosarcoma without methotrexate: results of the St Jude Children’s Research Hospital OS99 trial. Cancer. 2011;117(12):2770–2778.
   Web of Science ®Google Scholar
• Whelan J, McTiernan A, Cooper N, et al. Incidence and survival of malignant bone sarcomas in England 1979–2007. Int J Cancer. 2012;131(4): E508–E517.
   PubMed Web of Science ®Google Scholar
• Coley WB. II. Contribution to the knowledge of sarcoma. Ann Surg. 1891;14(3):199–220.
   PubMedGoogle Scholar
• Jeys LM, Grimer RJ, Carter SR, Tillman RM, Abudu A. Post operative infection and increased survival in osteosarcoma patients: are they associated? Ann Surg Oncol. 2007;14(10):2887–2895.
   PubMed Web of Science ®Google Scholar
• Lee JA, Kim MS, Kim DH, et al. Postoperative infection and survival in osteosarcoma patients. Ann Surg Oncol. 2009;16(1):147–151.
   Web of Science ®Google Scholar
• Moore C, Eslin D, Levy A, Roberson J, Giusti V, Sutphin R. Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatr Blood Cancer. 2010;55(6):1096–1102.
   Web of Science ®Google Scholar
• De Angulo G, Hernandez M, Morales-Arias J, et al. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr Hematol Oncol. 2007;29(1):48–52.
   PubMed Web of Science ®Google Scholar
• Arndt CA, Koshkina NV, Inwards CY, et al. Inhaled granulocyte- macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. A report from the Children’s Oncology Group. Clin Cancer Res. 2010;16(15):4024–4030.
   PubMed Web of Science ®Google Scholar
• Muller CR, Smeland S, Bauer HC, Saeter G, Strander H. Interferonalpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol. 2005;44(5):475–480.
   PubMed Web of Science ®Google Scholar
• Strander H, Bauer HC, Brosjo O, et al. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol. 1995;34(6):877–880.
   PubMed Web of Science ®Google Scholar
• Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol. 1984;2(6):617–624.
   PubMed Web of Science ®Google Scholar
• Asano T, Matsushima K, Kleinerman ES. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post- transcriptional levels. Cancer Immunol Immunother. 1994;38(1):16–22.
   PubMed Web of Science ®Google Scholar
• Nardin A, Lefebvre ML, Labroquere K, Faure O, Abastado JP Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets. 2006;6(2):123–133.
   Web of Science ®Google Scholar
• Fogler WE, Fidler IJ. Comparative interaction of free and liposome- encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes. Int J Immunopharmacol. 1987;9(2):141–150.
   Web of Science ®Google Scholar
• Sone S, Mutsuura S, Ogawara M, Tsubura E. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes. J Immunol. 1984;132(4):2105–2110.
   Web of Science ®Google Scholar
• Fidler IJ, Brown NO, Hart IR. Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously. J Biol Response Mod. 1985;4(3):298–309.
   Google Scholar
• Chi SN, Conklin LS, Qin J, et al. The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer. 2004;42(1):46–51.
   PubMed Web of Science ®Google Scholar
• Crompton BD, Goldsby RE, Weinberg VK, Feren R, O’Donnell RJ, Ablin AR. Survival after recurrence of osteosarcoma: a 20-year experience at a single institution. Pediatr Blood Cancer. 2006;47(3):255–259.
   PubMed Web of Science ®Google Scholar
• Anderson P. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol. 2006;2(3):333–343.
   PubMedGoogle Scholar
• Shiratsuchi A, Nakanishi Y. Phosphatidylserine-mediated phagocytosis of anticancer drug-treated cells by macrophages. J Biochem. 1999;126(6):1101–1106.
   Web of Science ®Google Scholar
• Murray JL, Kleinerman ES, Cunningham JE, et al. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol. 1989;7(12):1915–1925.
   PubMed Web of Science ®Google Scholar
• Landmann R, Obrist R, Denz H, et al. Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide. Biotherapy. 1993;7(1):1–12.
   Google Scholar
• Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol. 2006;6(1):9–20.
   PubMed Web of Science ®Google Scholar
• Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003;278(11):8869–8872.
   PubMed Web of Science ®Google Scholar
• Hedl M, Abraham C. Distinct roles for Nod2 protein and autocrine interleukin-lbeta in muramyl dipeptide-induced mitogen-activated protein kinase activation and cytokine secretion in human macrophages. J Biol Chem. 2011;286(30):26440–26449.
   Web of Science ®Google Scholar
• Hu C, Sun L, Hu Y, Lu D, Wang H, Tang S. Functional characterization of the NF-kappaB binding site in the human NOD2 promoter. Cell Mol Immunol. 2010;7(4):288–295.
   Web of Science ®Google Scholar
• Kleinerman ES, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res. 1983;43(5):2010–2014.
   Web of Science ®Google Scholar
• Dieter P, Ambs P, Fitzke E, Hidaka H, Hoffmann R, Schwende H. Comparative studies of cytotoxicity and the release of TNF-alpha, nitric oxide, and eicosanoids of liver macrophages treated with lipopolysaccharide and liposome-encapsulated MTP-PE. J Immunol. 1995;155(5):2595–2604.
   PubMed Web of Science ®Google Scholar
• Asano T, McWatters A, An T, Matsushima K, Kleinerman ES. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes. J Pharmacol Exp Ther. 1994;268(2):1032–1039.
   PubMed Web of Science ®Google Scholar
• Dieter P, Hempel U, Kamionka S, et al. Prostaglandin E2 affects differently the release of inflammatory mediators from resident macrophages by LPS and muramyl tripeptides. Mediators Inflamm. 1999;8(6):295–303.
   Web of Science ®Google Scholar
• Maeda M, Knowles RD, Kleinerman ES. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. Cancer Commun. 1991;3(10–11):313–321.
   Web of Science ®Google Scholar
• Asano T, McIntyre BW, Bednarczyk JL, Wygant JN, Kleinerman ES. Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes. Oncol Res. 1995;7(5):253–257.
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Raymond AK, Bucana CD, et al. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother. 1992;34(4):211–220.
   PubMed Web of Science ®Google Scholar
• Asano T, Fuj imaki W, McWatters A, An T, Matsu shima K, Kleinerman ES. Effect of Adriamycin on liposomal muramyl tripeptide’s ability to up- regulate monocyte cytokine expression. Cancer Immunol Immunother. 1993;37(6):408–411.
   Web of Science ®Google Scholar
• Bezault J, Walsh C, Tarcsay L, Frost H, Liebes L, Furmanski P. Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs. In Vivo. 1993;7(6A):487–491.
   Google Scholar
• Killion JJ, Kleinerman ES, Wilson MR, Tanaka M, Fidler IJ. Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents. Oncol Res. 1992;4(10):413–418.
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Snyder JS, Jaffe N. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J Clin Oncol. 1991;9(2):259–267.
   Web of Science ®Google Scholar
• Hisano G, Fidler IJ. Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin. Cancer Immunol Immunother. 1982;14(2):61–66.
   Web of Science ®Google Scholar
• Fujimaki W, Griffin JR, Kleinerman ES. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation? Cancer Immunol Immunother. 1993;36(1):45–51.
   PubMed Web of Science ®Google Scholar
• Ando K, Mori K, Corradini N, Redini F, Heymann D. Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother. 2011;12(2):285–292.
   PubMed Web of Science ®Google Scholar
• Meyers PA. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther. 2009;9(8):1035–1049.
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, Jaffe N. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol. 1995;17(3):181–193.
   PubMed Web of Science ®Google Scholar
• Creaven PJ, Cowens JW, Brenner DE, et al. Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. J Biol Response Mod. 1990;9(5):492–498.
   PubMedGoogle Scholar
• Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992;10(8):1310–1316.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004–2011.
   PubMed Web of Science ®Google Scholar
• Urba WJ, Hartmann LC, Longo DL, et al. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidyletha- nolamine. Cancer Res. 1990;50(10):2979–2986.
   Google Scholar
• Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group. J Clin Oncol. 2008;26(4):633–638.
   PubMed Web of Science ®Google Scholar
• Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer. 2009;115(22):5339–5348.
   PubMed Web of Science ®Google Scholar
• Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium- 153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002;20(1):189–196.
   PubMed Web of Science ®Google Scholar
• Loeb DM, Garrett-Mayer E, Hobbs RF, et al. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009;115(11):2514–2522.
   Web of Science ®Google Scholar